152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents.
CNS spectrums（2020）
摘要
The studies are sponsored by Teva Pharmaceuticals and operationalized by Teva's development partner, Nuvelution TS Pharma INC.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要